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scored on a 0 (no difficulty) to 10 (unable to do) numerical rating scale. sIFA items 
are aligned with the functional impact of sIBM described in the literature/expert 
review and identified as relevant and important to sIBM patients. The draft concep-
tual framework includes items related to upper extremity, lower extremity, general 
function and swallowing. Cognitive testing of paper and ePRO versions support 
the use of this tool in a broad functional range of sIBM patients. CONCLUSIONS: 
The sIFA is the first content valid tool developed specifically for use in the func-
tional assessment of treatment benefit in sIBM patients aligned with the FDA PRO 
Guidance. Psychometric evaluation is underway.
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OBJECTIVES: To identify and review the suitability of cystic fibrosis (CF)-specific 
clinical outcome assessments (COAs) for clinical trial assessment of novel CF thera-
pies and to support product labelling. METHODS: CF-specific COAs were identified 
through an in-depth literature search using pre-defined search terms and via clini-
caltrials.gov. COA utilization in CF clinical trials and previous success in supporting 
product labelling was also explored. In line with best-practice, conceptual coverage 
of identified COAs was assessed by mapping items to a patient-centered conceptual 
model of CF symptoms and impacts. COAs with the most comprehensive conceptual 
coverage were further evaluated for content validity, psychometric properties and 
feasibility of use. RESULTS: Nine CF-specific COAs were identified; Cystic Fibrosis 
Questionnaire-Revised (CFQ-R) [pediatric 6-11/12-13 years, 14+ years and parent-
report 6-13 years] and Cystic Fibrosis Respiratory Symptom Diary (CFRSD) were 
selected for in-depth review. CFQ-R 14+ provided the most comprehensive concep-
tual coverage, assessing 52% of patient-centered symptom concepts and 50% impact 
concepts. Pediatric and parent-reported versions of CFQ-R assessed fewer concepts. 
All versions of CFQ-R have acceptable psychometric properties and are linguistically 
validated in > 30 languages. CFQ-R has also supported previous EMA and FDA label 
claims for respiratory symptoms. Limitations include the acceptability of a 2-week 
recall period and inconsistencies in concepts measured across pediatric and adult 
versions. CFRSD provides a comprehensive assessment of 83% of acute respiratory 
symptoms and 32% of acute impacts and is currently under evaluation for FDA Drug 
Development Tool qualification by FDA. The respiratory symptom score has excel-
lent psychometric properties; impact items are yet to be validated. CONCLUSIONS: 
Although 9 CF-specific COAs were identified in this study, only the CFQ-R measures 
and CFRSD appear potentially suitable for assessment of CF-related symptoms and 
impacts in CF clinical trials. Further data relating to content validity of CFQ-R may 
be required to support future labelling approvals.
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OBJECTIVES: The 39-item Parkinson’s Disease Questionnaire (PDQ-39) is the most 
thoroughly validated and extensively used self-report measure for the assessment 
of health-related quality of life in people with Parkinson’s (PwP). The measure has 
been shown to possess sound psychometric properties and its use is widely recom-
mended. Given the extent of its use and increasing emphasis on electronic data 
capture, a web based version of the PDQ-39, the ePDQ, has been developed. The aim 
here is to present reliability and validity data that confirm the psychometric quality 
of the ePDQ. METHODS: Recruitment of participants was undertaken with the sup-
port of Parkinson’s UK. Participants were emailed a unique link to an online survey 
containing the ePDQ and demographic questions. RESULTS: A total of 118 PwP (66 
males, 52 females) fully completed the ePDQ, a response rate of 91.4%. The mean age 
was 63.48 years, mean disease duration 5.73 years and mean age at diagnosis 57.69 
years. Score reliability was assessed by item-total correlations which ranged from 
0.34 to 0.90. Cronbach’s alpha was calculated at between 0.64 and 0.95 for the eight 
domains of the ePDQ. Construct validity was assessed by comparing group means 
for disease duration and gender and all previously hypothesised differences were 
confirmed. Furthermore, a higher order factor analysis confirmed the appropriate-
ness of calculating a summary score index. CONCLUSIONS: Data indicates that the 
ePDQ possesses appropriate levels of reliability and validity and largely mirrors the 
psychometric properties of the paper-based version.
PND51
sex DiffereNCes iN over-the-CoUNter sleeP aiD Use iN olDer aDUlts
Gross H.J.1, O’Neill G.2, Toscani M.3, Chapnick J.4
1Kantar Health, Princeton, NJ, USA, 2Gerontological Society of America, Washington, DC, USA, 
3Ernest Mario School of Pharmacy, Piscataway, NJ, USA, 4Kantar Health, Horsham, PA, USA
OBJECTIVES: Over-the-counter (OTC) sleep aids are widely self-administered and 
are generally safe, but their primary ingredients (diphenhydramine and doxylamine 
(DPH/DOX)) may pose risks, especially in older adults who may use these products 
outside of their label recommendations. This analysis characterizes the use of DPH/
DOX for sleep disturbances by age and sex in older American adults. METHODS: 
Data were taken from the 2013 US National Health and Wellness Survey (NHWS), a 
cross-sectional, internet-based, IRB-approved annual survey of adults (N= 75,000). 
Stratified sampling was used to represent the demographic make-up of the general 
population in age, sex, and ethnicity. Weights were applied using age, sex, eth-
nicity, and education to reflect the US population. Respondents reporting regular 
sleeplessness symptoms and insomnia/sleep difficulties (SD) were included in the 
analysis. Comparisons between sexes were made using chi-square tests for cat-
egorical variables and t-tests for continuous variables. RESULTS: Of the projected 
41.3 M (n= 16,500) adults age ≥ 65, 15% (3.8 M age 65-74; 2.6 M age 75+) reported 
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OBJECTIVES: Patients with rare genetic diseases often experience a diagnostic odys-
sey; no diagnosis or a delay in obtaining a diagnosis, due to lengthy diagnostic 
work-ups. Whole-exome sequencing (WES) can rapidly identify the mutation(s) 
responsible for rare, single-gene diseases. Before incorporating this new technology 
into clinical practice, we must understand the value of diagnostic information. We 
aimed to identify key attributes surrounding the value of a diagnosis to develop a 
discrete choice experiment (DCE) survey to estimate the value of WES diagnostic 
information to parents of children with rare diseases. METHODS: We used a multi-
phase, mixed-methods approach to identify key attributes and levels. We conducted 
a literature review to identify an extensive list of candidate attributes. We used 
results from focus groups with parents of children (n= 15) and adults (n= 8) with 
rare diseases to identify additional attributes. Candidate attributes were refined 
by consultation with research team members (including medical geneticists). The 
DCE survey was pre-tested in a sample of parents of children with rare diseases 
(n= 5) and attributes were further refined. RESULTS: The DCE included six attributes, 
each with four levels: type of diagnostic (genomic sequencing, other genetic testing, 
operative procedures, series of tests and procedures); chance of a diagnosis (1/10, 
4/10, 6/10, 9/10); negative impact of diagnostic test results (lifestyle restrictions, 
victim of discrimination, labeled by others, no impact); positive impact of diagnos-
tic test results (lead to therapy); out-of-pocket cost ($250, $1000, $5000, $10,000); 
time to obtain a diagnosis (6 months, 3 years, 5 years, 10 years). CONCLUSIONS: 
The survey will be administered to n= 300 parents of children with rare diseases 
(diagnosed and undiagnosed) to evaluate willingness-to-pay for: WES, a diagnosis, 
and a faster diagnosis.
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OBJECTIVES: To identify and appraise the reporting on psychometric properties of 
selected patient reported outcome measures (PROs) used in multiple sclerosis (MS) 
Phase IV trials, and to identify PROs potentially suitable for Phase IV use. METHODS: 
We systematically searched PubMed, Clinicaltrials.gov, and MS conferences from 
2009 onwards to identify PROs used in MS Phase IV trials. For further assessment, 
we selected PROs on key MS concepts: health-related quality of life (HRQoL), mood/
depression, fatigue, and cognition. These PROs were appraised in the context of the 
U.S Food and Drug Administration guidance for work reporting on psychometric 
properties (validity, reliability, and responsiveness). RESULTS: A total of 24 PROs on 
the selected concepts were identified from 30 studies. PROs were MS-specific for 7 
of 13 HRQoL, 1 of 7 mood/depression, and 1 of 4 fatigue measures. No study reported 
using PROs that independently measure cognition, although most HRQoL and 
fatigue PROs have a mental/cognition subcomponent. Modern psychometric analy-
ses were conducted on MS International Quality of Life Questionnaire (MusiQoL), 
MS Impact Scale-29 (MSIS-29), MS Neuropsychological Screening Questionnaire 
(MSNQ), Fatigue Severity Scale (FSS), and Modified Fatigue Impact Scale (MFIS). 
MS-specific HRQoL PROs were well-validated and are potentially useful in trial set-
tings, namely MusiQoL, MSIS-29 and Hamburg QoL Questionnaire MS (HAQUAMS). 
The MSNQ, measuring mood/depression, reported reliability and content validity 
but have unknown construct validity and responsiveness. Generic PROs for mood/
depression generally lacked information on psychometric performance in MS 
patients. Among PROs measuring fatigue, FSS and MFIS appeared most promising 
for trial use, but did not have content validity for MS patients. CONCLUSIONS: 
Of the identified PROs, only a few were well-validated. More work is warranted to 
assess the suitability of insufficiently validated PROs for use in MS trials. Also, since 
mental deficit is a key concept in MS, future Phase IV trials should consider using 
PROs measuring cognition.
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OBJECTIVES: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by atrophy and weakness of proximal and distal muscle groups with the knee exten-
sors and wrist/finger flexors frequently involved as well as dysphagic processes. 
Progressive weakness results in a loss of independence and the need for assistive 
devices and supportive care. While no pharmacological treatments for sIBM are 
currently marketed, clinical trials are underway. To assess the potential treatment 
benefit of new therapies and track clinical progression, a patient-reported measure 
(PROM) of physical function, the siBM Physical functioning assessment (sIFA), was 
developed. METHODS: The sIFA was rigorously developed in accordance with the 
FDA PRO Guidance. This included literature review, medical expert and direct patient 
input. A single-visit, observational study involving sequential concept elicitation 
and cognitive debriefing interviews was conducted. Standard qualitative analytical 
methods were employed to analyze interview data and generate and pilot-test ques-
tionnaire items. RESULTS: Twenty concept elicitation and 19 cognitive debriefing 
interviews were conducted as well as consultation with six sIBM expert physicians. 
sIBM patients (n= 39) varied in age (mean= 67; range 46-81), duration of diagnosis 
(1 – 18 years), and functional impairment. The resultant PROM consists of 11 items 
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folic acid supplements use included awareness that folic acid prevent neural tube 
defects and perceived benefits that folic acid can prevent neural tube defects, and 
receiving advice from the doctor about using birth control. CONCLUSIONS: Although 
the women in this survey were aware and have knowledge that folic acid prevent 
birth defects; a large number of them reported not taking folic acid supplements. The 
reported consumption of folic acid was associated with the awareness and perceived 
benefits that folic acid use prevent NTDs. Therefore, it is important to raise aware-
ness about the beneficial effects of folic acid use among women of childbearing age.
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OBJECTIVES: To examine quality-of-life (QOL) predictors of treatment continua-
tion on eslicarbazepine acetate (ESL) monotherapy (1200 or 1600 mg/day) among 
subjects with partial epilepsy not well-controlled by current anti-epileptic drugs 
(AEDs). METHODS: Analysis of efficacy and QOL data from the pooled per-protocol 
population (n= 200) of two 18-week randomized clinical trials of ESL (045 and 046), 
both with an 8-week taper/conversion period and a 10-week efficacy period. The 
primary efficacy endpoint for these trials was study exit due to: worsening sei-
zure type, increased seizure frequency (SF), or investigator judgment. Predictors 
of monotherapy treatment continuation after 10 weeks were examined using 
stepwise logistic regression. Covariates included ESL dose, demographics, dis-
ease duration, baseline SF, baseline AEDs, number of AEDs, change in SF, and 
changes in the QOLIE-31 subscale scores (Cognitive Functioning, Emotional Well-
being, Energy/Fatigue, Medication Effects, Overall QOL, Seizure Worry [SW], and 
Social Functioning) during the taper/conversion period. A separate model included 
change in SF to test whether predictors were independent of efficacy during taper/
conversion. RESULTS: Change in SW during the 8-week taper/conversion period 
was the only predictor of remaining on ESL monotherapy. Mean change was 9.6 
(SD: 20.98) for 181 subjects remaining on monotherapy, indicating a reduction in 
worry. Mean change for 19 subjects who exited was -4.8 (SD: 20.79). Each point 
improvement in SW was associated with a 4% increase in the odds of remaining 
on monotherapy (odds ratio [OR]: 1.04; 95% CI: 1.01, 1.06). Results were similar with 
inclusion of SF change in this model (OR: 1.03; 95% CI: 1.01, 1.06). CONCLUSIONS: 
In this pooled, per-protocol population analysis, change in a subject’s level of 
seizure worry was moderately predictive of remaining on ESL monotherapy. This 
may be a surrogate for severity of epilepsy and the value of such predictors needs 
additional research and assessment.
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OBJECTIVES: Research examining epilepsy treatment satisfaction is lacking. The 
aim of this study is to compare treatment satisfaction among patients with epilepsy 
treated either with monotherapy or adjunctive therapy. METHODS: Data from the 
2011-2013 U.S. National Health and Wellness Survey (NHWS) were analyzed. The 
NHWS is a self-administered, internet-based survey of a nationwide sample of 
adults stratified to represent the demographic composition of the U.S. population. 
Patients who reported being treated with an antiepileptic drug (AED) for epilepsy 
were grouped as using monotherapy (one Rx) or adjunctive AED therapy (two or 
more Rxs). Patients provided information on treatment satisfaction with current 
epilepsy prescription medication (1 [extremely dissatisfied] to 7 [extremely satis-
fied]), demographics, and health characteristics (e.g., age, comorbidities [Charlson 
comorbidity index], epilepsy severity). Pairwise comparisons (Bonferroni adjusted) 
examined whether patients on monotherapy vs. adjunctive therapy differed in 
treatment satisfaction. RESULTS: Among 1,126 epilepsy patients (mean age= 46.33; 
47.70% female), 744 were on monotherapy (66.07%), 286 on two AEDs (25.40%), 65 on 
three AEDs (5.77%), and 31 on four or more AEDs (2.75%). Compared to monotherapy 
patients, treatment of patients with an increasing number of concomitant AEDs was 
associated with greater comorbidity burden (4+Rxs: 3.00 vs. monotherapy: 0.93), 
higher percentage of severe epilepsy (4+Rxs: 41.90% vs. monotherapy: 10.60%), and 
higher seizure frequency (4+Rxs: 35.50% vs. monotherapy: 7.30% for frequency > 
1/week), all p< .05. Patients on monotherapy (5.93) had higher treatment satisfac-
tion than patients on adjunctive therapy (4+Rxs: 4.78), p< .05. Additionally, among 
adjunctive therapy patients, those on 2Rxs (5.79) had higher satisfaction than those 
on 4+Rxs (4.78), p< .05. CONCLUSIONS: In this study, monotherapy patients were 
more satisfied with their epilepsy treatment than adjunctive therapy users. The 
lower satisfaction levels among adjunctively-treated patients may be associated 
with the number of concomitant AEDs, seizure severity or frequency, comorbid 
conditions, or a combination of these factors.
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OBJECTIVES: Neuromyelitis optica (NMO) is an inflammatory CNS disease, that pre-
sents with severe optic neuritis and transverse myelitis. It is often accompanied by 
severe motor and sensory disability. In the past few years, NMO has gained lot of inter-
est and shares a controversial relationship with multiple sclerosis (MS). It is not yet 
known whether NMO differs in its effect on quality of life (QoL) when compared with 
MS. We aimed to evaluate the QoL in patients with NMO by conducting a systematic 
regular sleeplessness symptoms and insomnia/SD. More women were affected; 
67% of patients age 65-74 (2.5 M) and 73% of patients age 75+ (1.9 M) were female 
(p’s< 0.05). Approximately 1.1 M patients age 65+ self-reported using a product con-
taining DPH/DOX. Women were more likely to use DPH/DOX than men (21% (526 
K) vs. 12% (150 K) age 65-74 (p< 0.05); 19% (348 K) vs. 11% age 75+ (76 K) (p> 0.05)). 
However, men using DPH/DOX reported taking it more mean days per month (14.4 
vs. 11.3 age 65-74 (p< 0.05); 18.4 vs. 13.7 age 75+ (p> 0.05)). CONCLUSIONS: An esti-
mated one million adults age 65+ self-reported using DPH/DOX, many on a regular 
basis. Women composed a larger proportion of users, though men reported using 
these products more frequently. Further study on the use and safety of these OTC 
agents in older populations is recommended.
PND52
bUrDeN of illNess for PatieNts With familial amyloiDotiC 
PolyNeUroPathy (faP) begiNs early aND iNCreases With Disease 
ProgressioN
Denoncourt R.N.1, Adams D.2, Coelho T.3, Bettencourt B.R.1, Plaisted A.1, Amitay O.1, Falzone R.1, 
Harrop J.1, White L.1, De Frutos R.1, Cehelsky J.1, Nochur S.1, Vaishnaw A.K.1, Gollob J.1
1Alnylam Pharmaceuticals, Cambridge, MA, USA, 2Centre Paris-Sud, APHP, Hopital de Bicetre, 
INSERM U788, Service de Neurologie, and Centre de Reference des Neuropathies Amyloides 
Familiales, Le Kremlin-Bicetre, France, 3Unidade Clinica de Paramiloidose, Hospital de Santo 
Antonio, Porto, Portugal
OBJECTIVES: Familial Amyloidotic Polyneuropathy (FAP) is a rare, inherited, progres-
sively debilitating disease with a high unmet medical need. The purpose of this 
analysis is to assess the impact of FAP on healthcare resource utilization, quality 
of life, employment status, and activities of daily living (ADLs). METHODS: A Phase 
2 open-label extension study of patisiran in FAP patients was utilized to collect 
patient-reported outcomes, including EQ-5D, Rasch-built Overall Disability Scale 
(R-ODS), and a healthcare resource utilization questionnaire. RESULTS: The study 
included 27 patients, 18 males and 9 females, 29-77 years of age. Baseline data 
are presented for 14 patients with a Polyneuropathy Disability (PND) Score I and 
13 patients with a PND Score ≥ II. Characterized by FAP Stage, 24 patients are FAP 
Stage 1 and 3 patients are FAP Stage 2. Two patients (PND Score ≥ II) reported a total 
of six hospitalizations due to FAP in the past 12 months, each for 3 or more nights 
in duration. Mean EQ-5D scores were 0.82 (PND Score I) and 0.74 (PND Score ≥ II). 
Patients reported their perceived health status on the EQ-VAS with mean scores of 
75 (PND Score I) and 60 (PND Score ≥ II). Ten patients (8/10 PND Score ≥ II) reported 
they cannot work because of FAP. Patients also reported inability to perform various 
ADLs. Most commonly, 77% of patients with PND Score ≥ II cannot stand for hours 
(14% in PND Score I) and 69% cannot run (21% in PND Score I). CONCLUSIONS: FAP 
patients experience considerable burden of illness early in the course of disease 
and this burden increases with disease progression. The factors described will be 
influential in the development of a comprehensive FAP cost-consequence analysis. 
Additional parameters may also be needed to fully capture the totality of burden.
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OBJECTIVES: Despite the wealth of qualitative studies exploring the experiences 
of patients with cystic fibrosis (CF), currently no conceptual model of CF exists. 
Conceptual models are a valuable way to communicate relevant patient-centered 
concepts and the relationships between them, and form an important frame-
work for understanding what to measure in clinical trials and practice. This study 
aimed to use patient-derived qualitative insights to develop a conceptual model 
of CF. METHODS: A targeted literature review was performed to identify qualita-
tive studies describing the lived-experience of patients (aged ≥ 6 years) with CF. 
CF social media forums were also reviewed to supplement the published data by 
providing patient-derived quotes where none existed in the literature. Data were 
coded using Atlas.Ti software, and analysed to develop the conceptual model. Where 
possible, any differences in concepts according to age were identified. RESULTS: 
31 qualitative articles and 26 social media entries were reviewed, containing data 
from patients aged 6-67 years. Data from these sources were synthesized to develop 
a conceptual model of CF, comprising: 23 symptom concepts categorized into 3 
domains (respiratory, gastrointestinal/urinary, flu-like symptoms), 28 impact con-
cepts categorised into 9 domains (social, financial difficulties, psychological, future 
concerns, daily activities, emotional, physical functioning, work or school, sleep), 
and 5 treatment satisfaction concepts categorised into 2 domains (satisfaction with 
treatment administration, treatment adherence). Differences in impact concepts 
were apparent based on the patient’s age, e.g. bullying was only reported by children 
and financial issues only by adults. CONCLUSIONS: To our knowledge, this is the 
first patient-centered conceptual model for CF, reflecting the symptom and impact 
burdens of CF on patients’ lives as identified through qualitative patient-derived 
data. As such, this model provides an important critical framework to assess the 
conceptual relevance and patient-centeredness of outcome assessments ahead of 
selection for future clinical trials and clinical practice.
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OBJECTIVES: To assess the factors that affect taking folic acid supplements among 
women of childbearing age. METHODS: A cross-sectional online survey was con-
ducted among women of childbearing age at West Virginia University (n= 179) from 
January to March 2014. Multinomial logistic regression model was used to examine 
the factors that affect taking folic acid supplements. RESULTS: Around 42% of par-
ticipants reported taking folic acid supplements. Factors that were associated with 
